Abstract 243P
Background
Cervical cancer ranks as 2nd leading cause of female cancer in Indonesia. Early detection of cervical cancer is crucial for early treatment and reduce risk of mortality. Despite the evidence of cervical cancer screening is associated with decrease mortality from this disease, the uptake for cervical cancer screening among Indonesian women in suburban area of Banten remains low. The aim of this study is to discover factors that associate with uptake of cervical cancer screening and report on cervical cancer prevalence among women in suburban area of Banten.
Methods
This is a cross sectional study that took the mass screening in 3 different primary health care in Banten, Indonesia. We included female who had never done screening for cervical cancer and aged 21-65 years old. Cervical sample were collected for Papanicolaou smear and evaluated by pathologist.
Results
Pap smears of 309 females were taken. It was observed that 74,11% (n = 229) of females were negative for cervical intraepithelial lesion or malignancy. Our data showed that 13,5% (n = 42) had bacterial vaginosis, 6.14% (n = 19) had candida infection. Respectively ,for low grade squamous intraepithelial lesion (LSIL) and high grade intraepithelial lesion were 2,26%( n = 7) and 1,61 % (n = 5). Cervical cancer was positive for 0.97% (n = 3) and 1.29% (n = 4) had atropic vaginitis. The significant predictor for uptake of cervical cancer screening were being married, older age, and knowing a person with cervical cancer with p value 0.004, 0,037 and <0,001. The only significant factor that contribute to reduce uptake of screening is did not know where to go for screening and the price of screening with p value of 0,024 and 0.017.
Conclusions
Mass screening and public education is a crucial step to reduce morbidity and mortality of cervical cancer. Poor hygiene environment in suburban region increase incidence of infection that lead to causative factors for cervical cancer. Intensification of primary health care for cancer screening is needed to reduce the national burden of cervical cancer in Indonesia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of Medicine, Pelita Harapan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract